biostudies-literatureArcher KJUS National Cancer InstituteU.S. National Library of MedicineColeman Leukemia Research FoundationNCI NIH HHSAmerican Society of HematologyNLM NIH HHSD. Warren Brown Family FoundationLeukemia Research FoundationLeukemia and Lymphoma Society28https://www.ebi.ac.uk/biostudies/studies/S-EPMC11068580biostudies-literatureUnknown17(1)Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there remains heterogeneity with respect to relapse-free survival (RFS) within these genetic-risk groups. Our training set included 306 adults on Alliance for Clinical Trials in Oncology studies with de novo CN-AML aged < 60 years who achieved a complete remission and for whom centrally reviewed cytogenetics, RNA-sequencing, and gene mutation data from diagnostic samples were available (Alliance trial A152010). To overcome deficiencies of the Cox proportional hazards model when long-term survivors are present, we developed a penalized semi-parametric mixture curJournal of hematology & oncologyIdentifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.PMC11068580UG1CA233327UG1CA233338UG1 CA233339U10CA180882R35 CA197734UG1 CA233327R01 LM013879UG1 CA233338P30CA016058R01LM013879U10 CA180882P30 CA016058R01 CA283574U24 CA196171U24CA196171U10 CA180821UG1 CA233331Braess JSpiekermann KUy GLHerold THiddemann WStock WMrozek KNicolet DMims ASMetzeler KHArcher KJFu HByrd JCEisfeld AKfalseIdentifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there remains heterogeneity with respect to relapse-free survival (RFS) within these genetic-risk groups. Our training set included 306 adults on Alliance for Clinical Trials in Oncology studies with de novo CN-AML aged < 60 years who achieved a complete remission and for whom centrally reviewed cytogenetics, RNA-sequencing, and gene mutation data from diagnostic samples were available (Alliance trial A152010). To overcome deficiencies of the Cox proportional hazards model when long-term survivors are present, we developed a penalized semi-parametric mixture cur2024-01-01T00:00:00Z2024 May2026-06-01T05:37:42.676Z2026-04-08T09:41:11.373ZS-EPMC110685803870278610.1186/s13045-024-01553-6